Komori
M&A and Subsidiary Changes4390IPS,Inc.Information and communications, services and other

Notice regarding the merger of a consolidated subsidiary and change in a specified subsidiary

The Company's Philippine consolidated subsidiaries SHSC and SLACC are scheduled to merge, with SHSC as the surviving company and SLACC as the disappearing company. Following the merger, SHSC is scheduled to change its name to Shinagawa Medical Group.

Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

This transaction

The Merger
Counterparty (target company)Shinagawa Healthcare Solutions Corporation, Shinagawa Lasik & Aesthetics Center Corporation
Disclosing companyIPS,Inc.
Voting rights ownership percentage

The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.

TimelineThe spacing between the points is proportional to the actual number of days.White points represent dates designated as scheduled dates in the document.
Target company

Operation of medical checkup and health screening centers, Operation of ophthalmology clinics, including myopia correction through LASIK surgery

Location Taguig City, Metro Manila, Philippines, Taguig City, Metro Manila, PhilippinesShare capital 350,000,000PHP, 232,396,015PHPDate of incorporation 10 June 2022, 10 February 2010
Net SalesPHP 237,161,347 (fiscal year ended December 2025), PHP 401,927,545 (fiscal year ended December 2025)
Operating profitPHP (25,869,570) (fiscal year ended December 2025), PHP 47,424,067 (fiscal year ended December 2025)
Net assetsPHP 85,642,939 (fiscal year ended December 2025), PHP 916,083,186 (fiscal year ended December 2025)
Consideration and expenses
Type of ConsiderationShares (shares of the surviving company allocated to shareholders of the disappearing company)
Impact on Business Performance

The impact of the merger on consolidated results for the fiscal year ending March 2027 will be immaterial.

Procedures and assumptions
Valuation methodologyBased on the enterprise value appraisals of SHSC and SLACC by the local audit firm as of 30 September 2026, after the audit
Independent valuation institutionLocal audit firm (name not disclosed)
Management structure after acquisitionThe surviving company will be SHSC, which is scheduled to change its name to Shinagawa Medical Group following the merger. The representative will be President Masako Uemori (Senior Managing Director of the Company). Employee treatment is Not disclosed.
This transaction
ItemDetails
Transaction nameThe Merger
Counterparty nameShinagawa Healthcare Solutions Corporation, Shinagawa Lasik & Aesthetics Center Corporation
Name of the Subject CompanyShinagawa Healthcare Solutions Corporation, Shinagawa Lasik & Aesthetics Center Corporation
Business Description of the Subject CompanyOperation of medical checkup and health screening centers, Operation of ophthalmology clinics, including myopia correction through LASIK surgery
Location of the Subject CompanyTaguig City, Metro Manila, Philippines, Taguig City, Metro Manila, Philippines
Capital Stock of the Subject Company350,000,000PHP, 232,396,015PHP
Date of Establishment of the Subject Company10 June 2022, 10 February 2010
Net Sales of the Subject CompanyPHP 237,161,347 (fiscal year ended December 2025), PHP 401,927,545 (fiscal year ended December 2025)
Operating Profit of the Subject CompanyPHP (25,869,570) (fiscal year ended December 2025), PHP 47,424,067 (fiscal year ended December 2025)
Net Assets of the Subject CompanyPHP 85,642,939 (fiscal year ended December 2025), PHP 916,083,186 (fiscal year ended December 2025)
Type of ConsiderationShares (shares of the surviving company allocated to shareholders of the disappearing company)
Voting rights ownership percentageBefore SHSC: 40% held by the Company; SLACC: 46.54% held by the Company → after Merged company: 48.47% held by the Company
Impact on Business PerformanceThe impact of the merger on consolidated results for the fiscal year ending March 2027 will be immaterial.
Date of board resolution20 November 2026
Contract DateDecember 2026 (予定)
Execution Date / Effective Date1 January 2027 (予定)
Valuation methodologyBased on the enterprise value appraisals of SHSC and SLACC by the local audit firm as of 30 September 2026, after the audit
Independent valuation institutionLocal audit firm (name not disclosed)
Management structure after acquisitionThe surviving company will be SHSC, which is scheduled to change its name to Shinagawa Medical Group following the merger. The representative will be President Masako Uemori (Senior Managing Director of the Company). Employee treatment is Not disclosed.
Items this document does not state (13)
Net Income of the Subject CompanyAcquisition priceExpenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Special CommitteeConditions Precedent to Execution

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To integrate the businesses of the 2 companies, simplify the organizational structure, improve management efficiency by strengthening management and optimizing the consolidation and allocation of management resources, and establish a foundation for medium- to long-term growth and strengthen competitiveness.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.